На главную
Результаты поиска “Oncatype dx breast cancer”
Oncotype DX for Early-stage Breast Cancer
 
04:46
Genomic Health, Inc. (NASDAQ: GHDX) today announced that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefit of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score® results of 11 to 25. The long-awaited results of the TAILORx study, the largest ever breast cancer treatment trial, sponsored by the National Cancer Institute (NCI), and led by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), provided definitive evidence that the Oncotype DX Breast Recurrence Score test identified 70 percent of early-stage breast cancer patients who receive no benefit from chemotherapy, and can be effectively treated with endocrine therapy alone. Additionally, the trial established that chemotherapy may provide life-saving benefit to 30 percent of patients. The TAILORx results will be published today in The New England Journal of Medicine in conjunction with a presentation during the Plenary Session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. To view the multimedia release go to: https://www.multivu.com/players/English/8335651-genomic-health-tailorx-oncotype-dx/
Просмотров: 541 MultiVu
When to Use the Oncotype DX® Breast Cancer Assay in Treatment Decisions
 
10:53
Dr. Hope Rugo explains what is the Oncotype DX Breast Cancer Assay and how is it performed, detailing the specificities of the test, especially how the Recurrence Score® result of the Oncotype DX Breast Cancer Assay is reported. She highlights the way, she and her multidisciplinary team, choose to use a genomic test such as the Oncotype DX Breast Cancer Assay to make adjuvant chemotherapy decisions in luminal breast cancers. She comments on the way to use the Oncotype DX Breast Cancer Assay: does it complement or compete with traditional markers or other markers such ER, PR or HER2? She mentions that the Recurrence Score result is very complementary and clarifies for which patients (ER+, HER2-, node positive or node negative) the Oncotype DX Breast Cancer Assay is indicated. _______________________________________________________ Hope Rugo, MD, is the Clinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology and Clinical Trials Education at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Просмотров: 3262 Genomic Health, Inc.
Less Chemotherapy for Breast Cancer: The TAILORx Results
 
12:19
We teach you about the TAILORx clinical trial results and how this information may save many women in the future from chemotherapy. VISIT THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/Breast-Cancer-School-for-Patients-958519147618444/ _________________________________ Questions for your Breast Surgeon and Medical Oncologist: *Do I qualify for an Oncotype DX genomic test? *If so, will you order genomic testing for me? *What if I have an "Intermediate" result? *Do you follow the "TAILORx" trial recommendations? *Would you order a genomic test before I see a medical oncologist? What does the TAILORx Clinical Trial results mean to me? On June 3rd, 2018 the results of the largest breast cancer trial reported results that help us better determine who MAY benefit or MAY NOT benefit from chemotherapy in early stage, favorable breast cancers. The results help patients and physicians better interpret the results from the genomic assay, Oncotype DX, which is commonly used in the United States. The trial concludes that most patients with an "Intermediate Recurrence Score" result may avoid chemotherapy. The results were also released for publication by the New England Journal of Medicine. Journal Article Link: https://www.nejm.org/doi/full/10.1056/NEJMoa1804710 Video Outlining the TAILORx Clinical Trial: https://www.youtube.com/watch?v=orwPgT0ZP_0&t=14s What is a genomic test? These sophisticated tests are performed on a small sample of cancer tissue in appropriate patients with early stage breast cancer. Genomic tests are usually ordered after surgery when the pathology report is finalized. It measures unique aspects of the tumor to determine if a patient will benefit from chemotherapy in addition to hormonal therapy. Such “genomic assays” developed over the last decade are a dramatic advance in breast cancer care. The Oncotype DX assay by Genomic Health Inc. is the most utilized genomic assay of those available in the United States. Who should consider a genomic test? Patients who have small “Estrogen receptor positive” (ER+) and “HER2 receptor negative” (HER2-) tumors and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX assay. The purpose of this test is to better identify people who do and do not benefit from chemotherapy. The decision to undergo chemotherapy is a complicated one. Your medical oncologist will examine multiple factors to help determine if you will benefit from chemotherapy. The NCCN Guidelines, listed in the website links below, outline in much greater detail recommendations for the use of genomic tests. An Oncotype DX test can be instrumental in this decision for many patients. You may qualify for a Genomic Assay if… You have early stage cancer (Stage I or II) Your tumor is Estrogen receptor positive (ER+) Your tumor is Her2 receptor negative (HER2-) No cancer was found in your lymph nodes You are willing to consider having chemotherapy You are healthy enough to undergo chemotherapy How is chemotherapy tailored to patients? Genomic breast cancer tests are a leap forward in our ability to “look inside” breast cancer cells. Sophisticated breast cancer care is based upon the principle of providing maximal benefit from the least toxic therapy. Newly diagnosed breast cancer patients deserve the best information available to decide whether they need chemotherapy. Take our video lesson on “Will I Need Chemotherapy?“ (here) to understand the general concepts. Genomics is a promising and rapidly developing field. Take Home Message: Make sure to ask both your breast surgeon and medical oncologist if a genomic assay might play a role in your treatment decisions. For appropriate patients, these tests should be considered only one piece of the many “pieces of the puzzle” in deciding treatment decisions about chemotherapy and hormonal therapy.
Просмотров: 21268 Breast Cancer School for Patients
The Oncotype DX Test: Understanding Your Breast Cancer Tumor
 
01:52
How do you know if chemotherapy is the best choice? What are the chances of your breast cancer coming back? The Oncotype DX Breast Cancer Assay was designed for breast cancer patients considering chemotherapy. Based on your tumor, the Oncotype DX test determines your DCIS Recurrence score on a scale of 0 - 100. Patients with a lower score have a smaller chance of breast cancer recurrence. This means that regardless of your DCIS score, you can feel confident when deciding the best course of cancer treatment and whether pursuing chemotherapy is right for you. Find out more about the Oncotype DX Breast Cancer Assay from Genomic Health’s Chief Medical Officer Dr. Steven Shak in the video above. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 1888 Breast Cancer Answers®
Genomic Testing in Breast Cancer: What You Must Know
 
14:37
We teach you about genomic testing and how these sophisticated tests can guide you to personalized therapies for your breast cancer. THE BREAST CANCER SCHOOL FOR PATIENTS: http://www.breastcancercourse.org LIST OF QUESTIONS FOR YOUR DOCTORS: http://www.breastcancercourse.org/breast-health-updates-latest-videos/ FOLLOW US: Facebook: https://www.facebook.com/BreastCancerSchoolForPatients/ ________________________________ Questions for your Breast Surgeon and Medical Oncologist: *Do I qualify for an Oncotype DX genomic test? *If so, will you order genomic testing for me? *Would you order a genomic test before I see a medical oncologist? *Are there any other genomic tests that apply to me? *What is a genomic assay? These sophisticated tests are performed on a small sample of cancer tissue in appropriate patients with early stage breast cancer. Genomic tests are usually ordered after surgery when the pathology report is finalized. It measures unique aspects of the tumor to determine if a patient will benefit from chemotherapy in addition to hormonal therapy. Such “genomic assays” developed over the last decade are a dramatic advance in breast cancer care. The Oncotype DX assay by Genomic Health Inc. is the most utilized genomic assay of those available in the United States. Who should consider a genomic test? Patients who have small “Estrogen receptor positive” (ER+) and “HER2 receptor negative” (HER2-) tumors and no evidence of cancer in their lymph nodes may benefit from an Oncotype DX assay. The purpose of this test is to better identify people who do and do not benefit from chemotherapy. The decision to undergo chemotherapy is a complicated one. Your medical oncologist will examine multiple factors to help determine if you will benefit from chemotherapy. The NCCN Guidelines, listed in the website links below, outline in much greater detail recommendations for the use of genomic tests. An Oncotype DX test can be instrumental in this decision for many patients. You may qualify for a Genomic Assay if… You have early stage cancer (Stage I or II) Your tumor is Estrogen receptor positive (ER+) Your tumor is Her2 receptor negative (HER2-) No cancer was found in your lymph nodes You are willing to consider having chemotherapy You are healthy enough to undergo chemotherapy How is chemotherapy tailored to patients? Genomic breast cancer tests are a leap forward in our ability to “look inside” breast cancer cells. Sophisticated breast cancer care is based upon the principle of providing maximal benefit from the least toxic therapy. Newly diagnosed breast cancer patients deserve the best information available to decide whether they need chemotherapy. Take our video lesson on “Will I Need Chemotherapy?“ (here) to understand the general concepts. Genomics is a promising and rapidly developing field. OTHER GENOMIC TESTS: Oncotype DX Breast DCIS Test This assay of DCIS or “precancerous” breast cells may help identify some women who may not benefit from radiation therapy after a lumpectomy. Genomic Health Inc. is a leading personalized medicine company. More information is about this test is located (here). MammaPrint This genomic test is used for Stage I and II breast cancers to determine prognosis and survival. This test is now included in national guidelines for some with hormone sensitive breast cancers that are found to have a small amount of cancer in a few lymph nodes. It is also a genomic test for some without “node positive” breast cancer. Agendia is a leader in personalized and molecular cancer diagnostics. More information about MammaPrint is located (here). Endopredict EndoPredict is a 2nd generation genomic breast cancer recurrence test to assess for 10-year risk of cancer recurrence. This test also accounts for tumor size in helping determine if chemotherapy may be needed in early stage, favorable breast cancers. Myriad Genetics is global leader in genetic testing and personalized medicine. More information about Endopredict is located (here). Breast Cancer Index (BCI) This test is designed for women with favorable, early stage breast cancer who have been on hormonal therapy for 4 to 5 years. It can help determine if someone will benefit (or can avoid) five additional years of hormonal therapy, such as tamoxifen or an aromatase inhibitor. This test is not yet approved by the FDA. Medicare and some insurance companies may cover the cost. Biotheranostics is a molecular diagnostics company. More information about BCI is located (here). Take Home Message: Make sure to ask both your breast surgeon and medical oncologist if a genomic assay might play a role in your treatment decisions. For appropriate patients, these tests should be considered only one piece of the many “pieces of the puzzle” in deciding treatment decisions about chemotherapy and hormonal therapy.
Просмотров: 1027 Breast Cancer School for Patients
Introducing the Oncotype DX® Breast Cancer Assay in the clinic
 
02:20
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses how genomic information from tests, such the Oncotype DX® Breast Cancer Assay, can be integrated with traditional clinicopathological information to support adjuvant clinical decision-making in breast cancer patients. This content is supported by Genomic Health, Inc.
Просмотров: 107 European Medical Group
Oncotype DX DCIS Breast Cancer Score: Amy's Story
 
01:40
Amy, a breast cancer survivor, describes her experience using Genomic Health's Oncotype DX DCIS Breast Cancer Score to personalize her treatment options. Share this video with your loved ones to help empower other women facing a DCIS (ductal carcinoma in situ) breast cancer diagnosis to ask for personalized treatment. For more information, please visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 9545 Genomic Health, Inc.
Design and rationale of PlanB trial of the Oncotype DX® Breast Cancer Assay in breast cancer
 
03:48
Dr. Oleg Gluz, from the West German Study Group, Mönchengladbach, Germany, talks about the rationale and design of PlanB, a prospective phase 3 trial evaluating the Oncotype DX® Recurrence Score® result for defining a low-risk subgroup of breast cancer patients with node-negative disease and high-risk clinicopathological factors as well as patients with node-positive disease who could be treated with adjuvant endocrine therapy alone. Recorded at the 10th European Breast Cancer Conference
Просмотров: 57 Genomic Health, Inc.
Oncotype DX Test: Risk and Recurrence in Breast Cancer, with Gonomic Health's Kim Popovits
 
03:18
Breast cancer recurrence and the Oncotype DX Breast Cancer Recurrence Score are detailed by Kim Popovits, Chairman, CEO and President at Genomic Health, Inc. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 2824 Genomic Health, Inc.
Overview of Oncotype DX Breast Cancer Assay for Patients
 
14:04
The Oncotype DX Breast Cancer Assay from Genomic Health is described, and breast cancer patients detail how the Oncotype DX helped them receive individualized and informative treatment options. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 462 Genomic Health, Inc.
Development of the Oncotype DX® Breast Cancer Assay
 
01:43
Breast cancer diagnostic tests have been revolutionized by the development of the Genomic Health Oncotype DX Breast Cancer Assay, as discussed by Dr. Steven Shak and Dr. Norman Wolmark. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 115 Genomic Health, Inc.
Breast Cancer Survivor Discusses the Oncotype DX Breast Cancer Assay - 2012 SABCS
 
01:22
Breast cancer survivor AnneMarie Ciccarella talks about her experience with Dr. Jay Harness, medical director at BreastCancerAnswers.com, at the 2012 San Antonio Breast Cancer Symposium. For more on AnneMarie's journey, please visit: http://chemo-brain.blogspot.com/ The live broadcast was sponsored by Genomic Health, the creator of Oncotype DX. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com
Просмотров: 2524 Genomic Health, Inc.
How the Oncotype DX® Breast Cancer Assay Has Changed Treatment for Patients
 
01:41
At the 2013 San Antonio Breast Cancer Symposium: The Oncotype DX Breast Cancer Assay and the way it helps breast cancer patients and their doctors create individualized treatment plans is discussed by Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Michael Alvarado, Director of Breast Surgery Oncology Fellowship at the University of California, San Francisco.
Просмотров: 857 Genomic Health, Inc.
Brief Overview of the Genomic Health Oncotype DX® Breast Cancer Assay
 
00:37
A quick look at the Genomic Health Oncotype DX Breast Cancer Assay. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 254 Genomic Health, Inc.
Oncotype DX Breast DCIS Score - Understanding Your Results
 
03:10
Prepare for your appointment with your doctor to review your Oncotype DX Breast DCIS Score results
Просмотров: 298 Genomic Health, Inc.
Oncotype DX Breast Recurrence Score Test -- What to Expect
 
02:20
Learn more about the Oncotype DX Breast Recurrence Score test and why your doctor ordered the test for you.
Просмотров: 607 Genomic Health, Inc.
How is the Oncotype DX Assay Used in Planning the Treatment for Patients with DCIS?
 
08:11
What is the Oncotype DX test, and how is it used to help plan treatment for DCIS patients? Watch as Dr. Harness discusses the Oncotype DX test and how it is impacting treatment options for DCIS patients. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR INFORMATIVE VIDEOS http://www.breastcanceranswers.com/video-categories/ SUBMIT A QUESTION http://www.breastcanceranswers.com/ask DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr ______ Disclaimer: This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Просмотров: 1793 Breast Cancer Answers®
DCIS (Stage 0) Breast Cancer and the Oncotype DX DCIS Score
 
02:53
Not all DCIS patients will benefit from the addition of radiation therapy to their treatment. Genomic Health's Oncotype DX Breast Cancer Assay for DCIS patients provides a DCIS score from which breast cancer doctors and their patients can determine the appropriate personalized treatment plan.
Просмотров: 33044 Genomic Health, Inc.
Oncotype DX Breast DCIS Score - What to Expect
 
03:43
Learn more about the Oncotype DX DCIS Score test and why your doctor ordered the test for you.
Просмотров: 152 Genomic Health, Inc.
Not All Breast Cancer Is The Same. Get Your Oncotype DX Score
 
02:33
Not all breast cancer is the same. Get your Oncotype DX score before you make your treatment decision.
Просмотров: 4943 Genomic Health, Inc.
Oncotype DX Breast Cancer Patient Stories
 
02:16
Women with breast cancer talk about how the Oncotype DX Breast Cancer Assay from Genomic Health helped them and their doctors make personalized treatment decisions. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 2454 Genomic Health, Inc.
Reasons to Take the Oncotype DX Breast Cancer Assay
 
01:09
Genomic Health's Chief Medical Officer Dr. Steven Shak shares some reasons why it's important to take the Oncotype DX Breast Cancer Assay. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 138 Breast Cancer Answers®
What Guidelines Say About the Oncotype DX® Breast Cancer Assay
 
02:46
At the 2013 San Antonio Breast Cancer Symposium: Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Christy Russell, Associate Professor of Clinical Oncology and Co-Director at the University of Southern California Norris Lee Breast Center (as of Jan 2017, Dr. Russell became Sr Director of Medical Affairs at Genomic Health), analyze the driving guidelines for Genomic Health's Oncotype DX Breast Cancer Assay. .
Просмотров: 314 Genomic Health, Inc.
DCIS Diagnosis & The Oncotype Breast Cancer Assay for DCIS
 
25:56
*DCIS Diagnosis & The Oncotype Breast Cancer Assay for DCIS* Genomic Health, Inc. reported positive results from an initial validation study of Oncotype DX® in patients suffering from a pre-invasive form of breast cancer, also known as ductal carcinoma in situ (DCIS). This is the second largest, independent clinical study of Oncotype DX. The Ontario DCIS Study Group in Canada conducted this clinical study which met its primary endpoint by substantiating that the Oncotype DX DCIS Score™ can predict the risk of local recurrence. Local recurrence indicates either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. DCIS is a stage zero breast cancer that affects 1 out of every 5 women in the U.S. The study revealed that approximately 80% of women diagnosed with DCIS currently receive unnecessary aggressive therapy, while others in need of it often miss the chance of undergoing the advance treatment. This often causes cancer to proliferate, which could have otherwise been avoided with proper treatment. However, the above-mentioned study showed that Oncotype DX can predict individual risk of recurrence and thereby help in taking suitable treatment decisions. This not only leads to timely treatment decisions but also reduces healthcare costs. The aforementioned study results represent the largest genomic study in DCIS to date. These results reaffirm the inferences of the previously-released validation study performed by the ECOG-ACRIN Cancer Research Group.  This is the first time the Oncotype DX DCIS Score has succeeded in predicting the risk of local recurrence in a group of patients treated with radiation therapy in clinical practice. The study involved more than 1,200 patients diagnosed with DCIS between 1994 and 2003. Researchers from Genomic Health collaborated with the Ontario DCIS Study Group to examine the tumor samples collected from these patients. The patient group constituted both patients treated with surgery alone and those treated with surgery plus radiation. Genomic Health and the Ontario DCIS Study Group plans to submit the results from this study at the 2014 San Antonio Breast Cancer Symposium in December. Recently, a clinical decision impact study presented at the American Society of Clinical Oncology revealed that the Oncotype DX DCIS Score results have changed treatment recommendations for 1 out of 3 patients with DCIS, highlighting the need for optimizing treatment of DCIS. The Oncotype DX DCIS Score looks at 12 genes within a tumor sample to reveal the aggressiveness of the disease. Join Medical Director Dr. Jay Harness along with co-founders of BreastCancerAnswers.com Todd Hartley & Wendy Hartley as they discuss getting diagnosed with DCIS and the Oncotype DX Breast Cancer Assay for DCIS patients. The live event will take place on April 2nd at 9 am PT/12 pm ET. To watch it on your mobile device, go to http://www.youtube.com/watch?v=zLAUX2x45Hc #ODX   #DCIS   #BreastCancer
Просмотров: 4693 Breast Cancer Answers®
Dr. Pat Whitworth Discusses Guidelines and the Oncotype DX® Breast Cancer Assay
 
08:56
Breast cancer guidelines and Genomic Health's Oncotype DX Breast Cancer Assay are discussed in an interview with Dr. Pat Whitworth. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 861 Genomic Health, Inc.
Difference Between the Ki-67 Tumor Marker Test and the Oncotype DX Test
 
05:31
Dr. Harness explains the difference between the Ki-67 test and Oncotype DX test. The Ki-67 test determines how rapidly cells are growing and, in turn, how the patient will respond to chemotherapy. The Oncotype DX test is a gene analysis test and helps doctors determine whether or not a patient will benefit from chemotherapy. Watch this video to learn more. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Просмотров: 7574 Breast Cancer Answers®
Does Health Insurance Cover Oncotype DX Breast Cancer Test?
 
01:32
Dr. Shak explains that the Oncotype DX is covered by many insurance plans, especially for women with node negative breast cancer. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Просмотров: 29166 Breast Cancer Answers®
Experience of the Oncotype DX® Breast Cancer Assay in the clinic
 
03:34
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses the controversy regarding the optimal approach to prognostic and predictive genomic testing for breast cancer. The Oncotype DX® Breast Cancer Assay, a 21-gene assay, may complement clinicopathological factors for defining subpopulations in breast cancer patients that would benefit from adjuvant chemotherapy. This content is supported by Genomic Health, Inc.
Просмотров: 56 European Medical Group
Jen D: DCIS/Stage 0 Breast Cancer Survivor - How Oncotype DX Impacted Her Treatment Decision
 
00:37
Jen D. credits her friends and family for introducing her to the Oncotype DX, which helped her guide her treatment decision for her DCIS/stage 0 breast cancer diagnosis.
Просмотров: 354 Genomic Health, Inc.
What Makes the Oncotype DX Breast Cancer Assay Different?
 
00:35
Jane O'Brien, breast surgeon, discusses how the Oncotype DX Breast Cancer Assay differs from other genomic assays
Просмотров: 50 Specialised Therapeutics
Impact of the Oncotype DX® Breast Cancer Assay in the Past Ten Years
 
03:33
At the 2013 San Antonio Breast Cancer Symposium: Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, and Dr. Lee Schwartzberg, Chief, Division of Hematology Oncology and Professor of Medicine at the University of Tennessee Health Science Center, discuss Genomic Health's Oncotype DX Breast Cancer Assay and how it has impacted breast cancer treatment decisions over the past ten years.
Просмотров: 317 Genomic Health, Inc.
Breast Cancer Molecular Test Benefits, Dr. Harness Explains the Oncotype DX
 
01:35
The score a patient receives from an Oncotype DX test will help determine if her cancer will come back elsewhere in her body, and if in fact she needs chemotherapy, or another type of treatment for her breast cancer. Dr. Harness explains the benefits of having this test for both the patient and her team of doctors. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, ‪http://www.breastcanceranswers.com/ask‬ This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk. If you have any concerns about your health, please consult with a physician.
Просмотров: 11739 Breast Cancer Answers®
Outcomes Matter -- Oncotype DX®
 
02:21
As the only test proven to predict chemotherapy benefit, the Oncotype DX Breast Recurrence Score® test is included in all major cancer guidelines worldwide and now considered as standard of care for women with early-stage breast cancer with results from the largest-ever adjuvent breast cancer treatment trial with over 10,000 patient participants.
Просмотров: 732 Genomic Health, Inc.
How the Oncotype DX Test Changed Treatment Decisions for 2 Women
 
04:26
Dr. Jay Harness shares how the Oncotype DX Breast Cancer Test changed the treatment decisions for 2 women. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 403 Breast Cancer Answers®
Oncotype DX Breast Cancer Test Impact On Treatment Options
 
01:21
The Oncotype DX Breast Cancer Test impacts treatment options in a positive way. Fortunately, today most women diagnosed with breast cancer will get an excellent long term survival, but knowing the underlying biology of the individual tumor is at the core of that fact. Dr. Shak explains more. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Просмотров: 38475 Breast Cancer Answers®
Oncotype DX Breast Cancer Assay (Chinese subtitle) - Part 2
 
06:15
A test that will help you and your doctor determine whether chemotherapy should be part of your treatment plan
Просмотров: 671 JacobsonMedical
Can Lymph Node-Positive Patients Take the Oncotype Dx Breast Cancer Assay?
 
02:06
In this video, Dr. Suzanne Klimberg explains how lymph node-positive breast cancer patients can benefit from the Oncotype Dx Breast Cancer Assay. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 133 Breast Cancer Answers®
Generating Oncotype DX® Test Results
 
01:44
Cancer tumor tissue is tested at the Genomic Health processing lab using the Oncotype DX diagnostic test. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 2254 Genomic Health, Inc.
Oncotype DX Breast Recurrence Score® - Understanding Your Results
 
02:26
Prepare for your appointment with your doctor to review your Oncotype DX Breast Recurrence Score results
Просмотров: 24 Genomic Health, Inc.
Oncotype Dx Breast Cancer Assay Cost & Insurance Coverage
 
01:22
SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 85 Breast Cancer Answers®
How to Get the Oncotype DX® Breast Cancer Test
 
00:47
Breast cancer patients can easily receive the Oncotype DX Breast Cancer Assay, according to Dr. Steven Shak of Genomic Health. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 308 Genomic Health, Inc.
The Genomic Road Map for Breast Cancer and Oncotype DX with Dr. Steven Shak - 2012 SABCS
 
02:04
Breast cancer and its genomic road map is the focus of conversation when Dr. Jay Harness, medical director of BreastCancerAnswers.com, is joined by Dr. Steven Shak, CMO at Genomic Health, at the 2012 San Antonio Breast Cancer Symposium. The live broadcast was sponsored by Genomic Health, the creator of Oncotype DX. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com
Просмотров: 3466 Genomic Health, Inc.
Oncotype DX Breast Cancer Test - CBS KLAS News
 
03:56
Dr. Larry Gardner, Medical Director of the Breast Center at Sunrise in Las Vegas, talks about the use of the Oncotype DX breast cancer test. Oncotype DX helps predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. Visit our website for more information: http://sunrisehospital.com/
Просмотров: 1037 Sunrise Hospital & Medical Center
The Oncotype DX® Breast Cancer Assay and Patients with Trace Amounts of Cancer in Lymph Nodes
 
02:42
At the 2013 San Antonio Breast Cancer Symposium: The Oncotype DX Breast Cancer Assay and patients with small amounts of cancer detected in their lymph nodes is the topic when Dr. Jay K. Harness, Medical Director at BreastCancerAnswers.com, sits down with Dr. Ruth O'Regan, Professor & Vice Chair of Educational Affairs in the Department of Hematology & Medical Oncology at Emory University.
Просмотров: 95 Genomic Health, Inc.
What is the Oncotype DX® Breast Cancer Test?
 
00:42
Breast cancer patients are helped by the OncoType DX Breast Cancer Assay in creating a personalized course of treatment. Dr. Steve Shak of Genomic Health explains how this has changed the way breast cancer is treated. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, visit: www.genomichealth.com www.oncotypedx.com
Просмотров: 350 Genomic Health, Inc.
Can I Avoid Chemotherapy Breast Cancer Treatment?
 
02:58
In this video, Dr. Margileth discusses the Oncotype DX test and how it determines if chemotherapy is the right treatment for you. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 1289 Breast Cancer Answers®
Breast Cancer Recurrence Prediction with Oncotype DX Test
 
01:26
For many breast cancer patients and their families knowing their risk for developing breast cancer for a second or even third time is vital and scary information. The Oncotype DX test gives patients a DCIS recurrence score, allowing them to make decisions for additional treatment. Click Here & Get The 15 Breast Cancer Questions To Ask Your Doctor http://www.breastcanceranswers.com/what-breast-cancer-questions-to-ask/# Breast Cancer Answers is a social media show where viewers submit a question and get the answer from an expert. Submit your question now at, http://www.breastcanceranswers.com/ask. This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided on this site solely at your own risk.  If you have any concerns about your health, please consult with a physician.
Просмотров: 15962 Breast Cancer Answers®
Ask for Answers: Will Chemotherapy Benefit Your Breast Cancer?
 
00:31
Only 4 of 100 women with early-stage invasive breast cancer benefit from chemotherapy*, and its toxic nature can result in severe side effects. Oncotype DX is the only test that can help you find out if chemotherapy is the best treatment for you—or if there is another option that might suit you better. Oncotype DX gives you personalized information about your individual breast cancer diagnosis. This can be used to help tailor treatment for your breast cancer. The test is intended to be used for patients with early-stage, node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy. Genomic Health is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. For more information, please visit: www.genomichealth.com or www.oncotypedx.com. * Lancet 1996 Apr 20; 347(9008):1006-71
Просмотров: 126862 Genomic Health, Inc.
How is the Oncotype DX Assay Used In Planning Breast Cancer Treatment?
 
08:11
Breast Cancer Answers Medical Director Dr. Jay Harness shares how the Oncotype DX Breast Cancer Assay is used in planning your breast cancer treatment. From this test, you will be able to determine if you need chemotherapy or radiation treatment. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancer... Twitter: https://twitter.com/BreastCancerDr
Просмотров: 154 Breast Cancer Answers®
What is the Oncotype DX for DCIS test?
 
02:01
How do you know how aggressive your treatment should be if you have DCIS (Stage 0) Breast Cancer. In this video Dr. Steve Shak talks about this topic and a test that can change your treatment decision. SUBSCRIBE FOR MORE EXPERT INFORMATION AND BREAKING BREAST CANCER NEWS http://www.youtube.com/user/drjayharness VISIT BREASTCANCERANSWERS.com FOR THE LATEST IN BREAKING BREAST CANCER NEWS http://www.breastcanceranswers.com/news SUBMIT A QUESTION http://www.breastcanceranswers.com/ DOWNLOAD DR. HARNESS' 15 QUESTIONS TO ASK YOUR DOCTOR http://www.breastcanceranswers.com/ CONNECT WITH US! Google+: http://bit.ly/16nhEnr Facebook: https://www.facebook.com/BreastCancerAnswers Twitter: https://twitter.com/BreastCancerDr
Просмотров: 353 Breast Cancer Answers®